Transverse Observables and Mass Determination at Hadron Colliders

I consider the two-body decay of a particle at a hadron collider into a visible and an invisible particle, generalizing $W \to e \nu$, where the masses of the decaying particle and the invisible decay particle are, {\em a priori}, unknown. I prove that the transverse mass, when maximized over possible kinematic configurations, can be used to determine both of the unknown masses. I argue that the proof can be generalized to cover cases such as decays of pair-produced superpartners to the lightest, stable superpartner at the Large Hadron Collider.Comment: 4 pages; version published in JHE

Fracture driven by a Thermal Gradient

Motivated by recent experiments by Yuse and Sano (Nature, 362, 329 (1993)), we propose a discrete model of linear springs for studying fracture in thin and elastically isotropic brittle films. The method enables us to draw a map of the stresses in the material. Cracks generated by the model, imposing a moving thermal gradient in the material, can branch or wiggle depending on the driving parameters. The results may be used to compare with other recent theoretical work, or to design future experiments.Comment: RevTeX file (9 pages) and 5 postscript figure

Challenges in the Analysis of Historic Concrete:Understanding the Limitations of Techniques, the Variability of the Material and the Importance of Representative Samples

The number of historically-significant concrete structures which require conservation and repair is ever-increasing. The use of unsuitable proprietary materials has led to poor quality repairs of historically-significant structures in the United Kingdom, some of which have resulted in damage to the historic character of the structure and accelerated deterioration of the substrate. As a result, the approach to the repair of historic concrete structures has shifted from the use of mass-produced proprietary repair materials to purpose-made ‘like-for-like’ replacements which, theoretically, have similar mechanical and aesthetic properties. In order to create like-for-like repair materials, the original mix proportions and water/cement (w/c) ratio of the substrate have to be established. However, there are concerns regarding the accuracy of existing techniques and standards used for the analyses of hardened concrete. Furthermore, due to a lack of available material, analyses are often carried out on samples that are much smaller than the minimum requirement for a representative sample, or from areas which are not representative. This paper discusses these issues and hopes to provide information to conservators and analysts on the limitations of techniques, the variability of the material and the importance of representative samples

Laser shock peening without absorbent coating (LSPwC) effect on 3D surface topography and mechanical properties of 6082-T651 Al alloy

The influence of nanosecond laser pulses applied by laser shock peening without absorbent coating (LSPwC) with a Q-switched Nd:YAG laser operating at a wavelength of λ = 1064 nm on 6082-T651 Al alloy has been investigated. The first portion of the present study assesses laser shock peening effect at two pulse densities on three-dimensional (3D) surface topography characteristics. In the second part of the study, the peening effect on surface texture orientation and micro-structure modification, i.e. the effect of surface craters due to plasma and shock waves, were investigated in both longitudinal (L) and transverse (T) directions of the laser-beam movement. In the final portion of the study, the changes of mechanical properties were evaluated with a residual stress profile and Vickers micro-hardness through depth variation in the near surface layer, whereas factorial design with a response surface methodology (RSM) was applied. The surface topographic and micro-structural effect of laser shock peening were characterised with optical microscopy, InfiniteFocus® microscopy and scanning electron microscopy (SEM). Residual stress evaluation based on a hole-drilling integral method confirmed higher compression at the near surface layer (33 μm) in the transverse direction (σmin) of laser-beam movement, i.e. − 407 ± 81 MPa and − 346 ± 124 MPa, after 900 and 2500 pulses/cm2, respectively. Moreover, RSM analysis of micro-hardness through depth distribution confirmed an increase at both pulse densities, whereas LSPwC-generated shock waves showed the impact effect of up to 800 μm below the surface. Furthermore, ANOVA results confirmed the insignificant influence of LSPwC treatment direction on micro-hardness distribution indicating essentially homogeneous conditions, in both L and T directions

Cross-national variations in reported discrimination among people treated for major depression worldwide : the ASPEN/INDIGO international study

No study has so far explored differences in discrimination reported by people with major depressive disorder (MDD) across countries and cultures. To (a) compare reported discrimination across different countries, and (b) explore the relative weight of individual and contextual factors in explaining levels of reported discrimination in people with MDD. Cross-sectional multisite international survey (34 countries worldwide) of 1082 people with MDD. Experienced and anticipated discrimination were assessed by the Discrimination and Stigma Scale (DISC). Countries were classified according to their rating on the Human Development Index (HDI). Multilevel negative binomial and Poisson models were used. People living in ‘very high HDI’ countries reported higher discrimination than those in ‘medium/low HDI’ countries. Variation in reported discrimination across countries was only partially explained by individual-level variables. The contribution of country-level variables was significant for anticipated discrimination only. Contextual factors play an important role in anticipated discrimination. Country-specific interventions should be implemented to prevent discrimination towards people with MDD

Integration of multiple data sources to prioritize candidate genes using discounted rating system

Background: Identifying disease gene from a list of candidate genes is an important task in bioinformatics. The main strategy is to prioritize candidate genes based on their similarity to known disease genes. Most of existing gene prioritization methods access only one genomic data source, which is noisy and incomplete. Thus, there is a need for the integration of multiple data sources containing different information. Results: In this paper, we proposed a combination strategy, called discounted rating system (DRS). We performed leave one out cross validation to compare it with N-dimensional order statistics (NDOS) used in Endeavour. Results showed that the AUC (Area Under the Curve) values achieved by DRS were comparable with NDOS on most of the disease families. But DRS worked much faster than NDOS, especially when the number of data sources increases. When there are 100 candidate genes and 20 data sources, DRS works more than 180 times faster than NDOS. In the framework of DRS, we give different weights for different data sources. The weighted DRS achieved significantly higher AUC values than NDOS. Conclusion: The proposed DRS algorithm is a powerful and effective framework for candidate gene prioritization. If weights of different data sources are proper given, the DRS algorithm will perform better

Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery—a pilot study

The perioperative administration of selective cyclooxygenase-2 (COX-2)-inhibitors to avoid postoperative pain is an attractive option: they show favorable gastro-intestinal tolerability, lack inhibition of blood coagulation, and carry a low risk of asthmatic attacks. The purpose of this study was to determine the cerebrospinal fluid (CSF), plasma, and tissue pharmacokinetics of orally administered etoricoxib and to compare it with effect data, i.e., COX-2-inhibition in patients after hip surgery. The study was performed in a blinded, randomized, parallel group design. A total of 12 adult patients were included who received 120 mg etoricoxib (n = 8) or placebo (n = 4) on day 1 post-surgery. Samples from plasma, CSF, and tissue exudates were collected over a period of 24 h post-dosing and analyzed for etoricoxib and prostaglandin E2 (PGE2) using liquid chromatography-tandem mass spectrometry and immuno-assay techniques. CSF area under the curve (AUC) [AUCs(O–24h)] for etoricoxib amounted to about 5% of the total AUC in plasma (range: 2–7%). Individual CSF lag times with respect to (50%) peak plasma concentration were ≤2 h in all but one case (median: 1 h). PGE2 production in tissue was significantly blocked by the COX-2 inhibitor starting with the appearance of etoricoxib in tissue and lasting for the whole observation period of 24 h (P < 0.01). In conclusion, etoricoxib reaches the CSF and site of surgery at effective concentrations and reduces PGE2 production at the presumed site of action

Minimising treatment-associated risks in systemic cancer therapy

Aim of the review To review the consequences of drug-related problems (DRP) in systemic cancer therapy and identify specific contributions of the pharmacist to minimise treatment-associated risks. Method Searches in PubMed, Embase and the Cochrane Library were conducted. Bibliographies of retrieved articles were examined for additional references. Only papers in English between 1980 and 2007 were included. Results In systemic cancer therapy there is an enormous potential for DRP due to the high toxicity and the complexity of most therapeutic regimens. The most frequently reported DRP can be classified into adverse effects, drug–drug interactions, medication errors, and non-adherence. Pharmacists have enhanced efforts to assure quality and safety in systemic cancer therapy together with other health care providers. In consequence, oncology pharmacy has evolved as a novel specialist discipline. The endeavour to merge and co-ordinate individual activities and services of the pharmacist has led to pharmaceutical care concepts which aim at offering novel solutions to the various DRP. Conclusion Pharmaceutical care for cancer patients should be developed within research projects and integrated into disease management programs in order to ensure broad implementation